En Es
Categories

Eurofins Technologies

Eurofins Technologies

Eurofins Technologies, part of the Eurofins Scientific group, is a fast-growing, global provider of diagnostic test kits and lab consumables in the fields of bioanalytical testing for the food, feed, environmental, biopharma, and clinical industries. The company offers a broad range of product test kits for Pathogens ...
Gold member
Products Covid-19NewsSummary
Close

Covid-19 Eurofins Technologies

Clinical Laboratory

SARS-CoV-2 RT-PCR Assays
GSD NovaType Select SARS-CoV-2 Assay Family

GSD NovaType Select is a group of RT-PCR assays to discriminate variants of the SARS-CoV-2 virus. The assay family provides the opportunity to assemble a customized RT-PCR assay mutation panel from a basis kit including the enzyme mastermix, and a range of mutation specific sets, including primer, probes and controls. The research use only (RUO) Select assays detect the following mutations: K417N, K417T, L452R, T478K, E484K, P681R and P618H.
More details

SARS-CoV-2 RT-PCR Test
GSD NovaType III SARS-CoV-2

The GSD NovaType III SARS-CoV-2 RT-PCR is developed for the rapid detection of SARS-CoV-2 variants of concern including B.1.427 / B.1.429 (Epsilon) / B.1.617.2 (Delta), B.1.617.1 (Kappa)/B.1.617.3, B.1.351 (Beta)/ P.1 (Gamma). The assay is intended as a confirmatory test for potential mutants and should only be performed after first testing patient specimens for the presence of SARS-CoV-2 RNA with a CE-IVD marked screening assay such as the GSD NovaPrime SARS-CoV-2 (COVID-19) RT-PCR kit.
More details

SARS-CoV-2 Multiplex Real-Time RT-PCR Assay
GSD NovaPrime Plus SARS-CoV-2

The CE-marked GSD NovaPrime Plus SARS-CoV-2 is a new Multiplex Real-Time RT-PCR assay intended for the qualitative detection of SARS-CoV-2 and the simultaneous discrimination of B.1.1.7 (Alpha), B.1.351 (Beta), and B.1.1.248 (P.1) (Gamma) lineages in one reaction.
More details

SARS-CoV-2 RT-PCR Assay
GSD NovaType II SARS-CoV-2

The GSD NovaType II SARS-CoV-2 Real-Time RT-PCR assay allows for the identification of relevant mutations associated with SARS-CoV-2 variants: B.1.1.7 (UK), B.1.351 (South Africa), and B.1.1.28 (P.1) (Brazil). The assay is intended as a confirmatory test for potential mutants and should only be performed after first testing patient specimens for the presence of SARS-CoV-2 RNA with a CE-IVD marked screening assay such as the GSD NovaPrime SARS-CoV-2 (COVID-19) RT-PCR kit.
More details

SARS-CoV-2 Ag Rapid Test (Nasal Swab)
GSD NovaGen SARS-CoV-2 Ag Rapid Test (Nasal Swab)

The GSD NovaGen SARS-CoV-2 Ag Rapid Test (Nasal Swab) is a rapid chromatographic immunoassay for the qualitative detection of SARS-CoV-2 Nucleocapsid Protein antigens present in nasopharyngeal swab specimen. The CE-IVD labeled rapid test detects SARS-CoV-2 antigens in 15 minutes with a diagnostic sensitivity of 92.6% and diagnostic specificity of 98.6%.
More details

SARS-CoV-2 IgG ELISA Kit
NovaLisa SARS-CoV-2 IgG

The NovaLisa SARS-CoV-2 IgG ELISA kit is intended for the qualitative detection of antibodies to the SARS-CoV-2 virus in human serum and plasma for diagnostics of exposure to coronavirus (COVID-19). The CE-IVD marked assay demonstrates high sensitivity with antibodies detected in all tested samples from patients PCR positive for SARS-CoV-2 12 days after symptom onset (100% sensitivity in this patient group), and a specificity of >98%.
More details

SARS-CoV-2 (COVID-19) Test
GSD NovaPrime® SARS-CoV-2 (COVID-19) RT-PCR

The GSD NovaPrime® SARS-CoV-2 (COVID-19) RT-PCR is intended for the qualitative determination of SARS-CoV-2 (Severe acute respiratory syndrome coronavirus 2) genomic RNA extracted from human respiratory (nasal wash/swab, nasopharyngeal wash/swab, oropharyngeal swab and bronchoalveolar lavage) specimen types. The assay simultaneously detects two target sequences inside the N gene while the multiplex PCR allows a streamlined workflow in one reaction and provides results in approximately two hours.
More details

SARS-CoV-2 (COVID-19) Antibody Test
INgezim COVID 19 DR

The INgezim COVID assays use the SARS-CoV-2 nucleoprotein (N protein) as the antigen for the detection of antibodies to SARS-CoV-2. The dual recognition enzyme-linked immunosorbent assay (ELISA) capable of detecting semi-quantitatively total SARS-CoV-2 virus N-protein-specific antibodies (IgG, IgM and IgA) in a single human serum or plasma sample.
More details

SARS-CoV-2 (COVID-19) Antibody Test
INgezim COVID 19 CROM

The INgezim COVID 19 CROM is a dual recognition immunochromatographic assay capable of detecting specific COVID-19 (SARS-CoV-2) antibodies (IgG, IgA, and IgM) in serum and blood samples. The test is able to detect antibodies specific to SARS-CoV-2 in 94.5% of cases from day 19. There is no cross-reactivity with antibodies specific to other coronaviruses or agents related to human respiratory illnesses.
More details
Close

News of Eurofins Technologies

Eurofins to Acquire Genetic Testing Services Provider DNA Diagnostics Center

29 Jun 2021
Eurofins to Acquire Genetic Testing Services Provider DNA Diagnostics Center
Eurofins Scientific (Ebersberg, Germany) has announces that its subsidiary Eurofins Clinical Testing US Holdings, Inc. has entered into an agreement to acquire DNA Diagnostics Center (DDC; Fairfield, OH, USA).
Read More
Close

About Eurofins Technologies

Eurofins Technologies, part of the Eurofins Scientific group, is a fast-growing, global provider of diagnostic test kits and lab consumables in the fields of bioanalytical testing for the food, feed, environmental, biopharma, and clinical industries. The company offers a broad range of product test kits for Pathogens, Allergens, GMOs, Mycotoxins, Veterinary Drugs Residues, Animal Species and Water testing.

Recently updated

SARS-CoV-2 Multiplex Real-Time RT-PCR Assay
GSD NovaPrime Plus SARS-CoV-2

The CE-marked GSD NovaPrime Plus SARS-CoV-2 is a new Multiplex Real-Time RT-PCR assay intended for the qualitative detection of SARS-CoV-2 and the simultaneous discrimination of B.1.1.7 (Alpha), B.1.351 (Beta), and B.1.1.248 (P.1) (Gamma) lineages in one reaction.
More details

SARS-CoV-2 RT-PCR Test
GSD NovaType III SARS-CoV-2

The GSD NovaType III SARS-CoV-2 RT-PCR is developed for the rapid detection of SARS-CoV-2 variants of concern including B.1.427 / B.1.429 (Epsilon) / B.1.617.2 (Delta), B.1.617.1 (Kappa)/B.1.617.3, B.1.351 (Beta)/ P.1 (Gamma). The assay is intended as a confirmatory test for potential mutants and should only be performed after first testing patient specimens for the presence of SARS-CoV-2 RNA with a CE-IVD marked screening assay such as the GSD NovaPrime SARS-CoV-2 (COVID-19) RT-PCR kit.
More details

SARS-CoV-2 RT-PCR Assays
GSD NovaType Select SARS-CoV-2 Assay Family

GSD NovaType Select is a group of RT-PCR assays to discriminate variants of the SARS-CoV-2 virus. The assay family provides the opportunity to assemble a customized RT-PCR assay mutation panel from a basis kit including the enzyme mastermix, and a range of mutation specific sets, including primer, probes and controls. The research use only (RUO) Select assays detect the following mutations: K417N, K417T, L452R, T478K, E484K, P681R and P618H.
More details

Clinical Laboratory

SARS-CoV-2 Multiplex Real-Time RT-PCR Assay
GSD NovaPrime Plus SARS-CoV-2

The CE-marked GSD NovaPrime Plus SARS-CoV-2 is a new Multiplex Real-Time RT-PCR assay intended for the qualitative detection of SARS-CoV-2 and the simultaneous discrimination of B.1.1.7 (Alpha), B.1.351 (Beta), and B.1.1.248 (P.1) (Gamma) lineages in one reaction.
More details

SARS-CoV-2 RT-PCR Test
GSD NovaType III SARS-CoV-2

The GSD NovaType III SARS-CoV-2 RT-PCR is developed for the rapid detection of SARS-CoV-2 variants of concern including B.1.427 / B.1.429 (Epsilon) / B.1.617.2 (Delta), B.1.617.1 (Kappa)/B.1.617.3, B.1.351 (Beta)/ P.1 (Gamma). The assay is intended as a confirmatory test for potential mutants and should only be performed after first testing patient specimens for the presence of SARS-CoV-2 RNA with a CE-IVD marked screening assay such as the GSD NovaPrime SARS-CoV-2 (COVID-19) RT-PCR kit.
More details

SARS-CoV-2 RT-PCR Assays
GSD NovaType Select SARS-CoV-2 Assay Family

GSD NovaType Select is a group of RT-PCR assays to discriminate variants of the SARS-CoV-2 virus. The assay family provides the opportunity to assemble a customized RT-PCR assay mutation panel from a basis kit including the enzyme mastermix, and a range of mutation specific sets, including primer, probes and controls. The research use only (RUO) Select assays detect the following mutations: K417N, K417T, L452R, T478K, E484K, P681R and P618H.
More details

SARS-CoV-2 IgG ELISA Kit
NovaLisa SARS-CoV-2 IgG

The NovaLisa SARS-CoV-2 IgG ELISA kit is intended for the qualitative detection of antibodies to the SARS-CoV-2 virus in human serum and plasma for diagnostics of exposure to coronavirus (COVID-19). The CE-IVD marked assay demonstrates high sensitivity with antibodies detected in all tested samples from patients PCR positive for SARS-CoV-2 12 days after symptom onset (100% sensitivity in this patient group), and a specificity of >98%.
More details

SARS-CoV-2 Ag Rapid Test (Nasal Swab)
GSD NovaGen SARS-CoV-2 Ag Rapid Test (Nasal Swab)

The GSD NovaGen SARS-CoV-2 Ag Rapid Test (Nasal Swab) is a rapid chromatographic immunoassay for the qualitative detection of SARS-CoV-2 Nucleocapsid Protein antigens present in nasopharyngeal swab specimen. The CE-IVD labeled rapid test detects SARS-CoV-2 antigens in 15 minutes with a diagnostic sensitivity of 92.6% and diagnostic specificity of 98.6%.
More details

SARS-CoV-2 RT-PCR Assay
GSD NovaType II SARS-CoV-2

The GSD NovaType II SARS-CoV-2 Real-Time RT-PCR assay allows for the identification of relevant mutations associated with SARS-CoV-2 variants: B.1.1.7 (UK), B.1.351 (South Africa), and B.1.1.28 (P.1) (Brazil). The assay is intended as a confirmatory test for potential mutants and should only be performed after first testing patient specimens for the presence of SARS-CoV-2 RNA with a CE-IVD marked screening assay such as the GSD NovaPrime SARS-CoV-2 (COVID-19) RT-PCR kit.
More details

SARS-CoV-2 (COVID-19) Antibody Test
INgezim COVID 19 CROM

The INgezim COVID 19 CROM is a dual recognition immunochromatographic assay capable of detecting specific COVID-19 (SARS-CoV-2) antibodies (IgG, IgA, and IgM) in serum and blood samples. The test is able to detect antibodies specific to SARS-CoV-2 in 94.5% of cases from day 19. There is no cross-reactivity with antibodies specific to other coronaviruses or agents related to human respiratory illnesses.
More details

SARS-CoV-2 (COVID-19) Antibody Test
INgezim COVID 19 DR

The INgezim COVID assays use the SARS-CoV-2 nucleoprotein (N protein) as the antigen for the detection of antibodies to SARS-CoV-2. The dual recognition enzyme-linked immunosorbent assay (ELISA) capable of detecting semi-quantitatively total SARS-CoV-2 virus N-protein-specific antibodies (IgG, IgM and IgA) in a single human serum or plasma sample.
More details

SARS-CoV-2 (COVID-19) Test
GSD NovaPrime® SARS-CoV-2 (COVID-19) RT-PCR

The GSD NovaPrime® SARS-CoV-2 (COVID-19) RT-PCR is intended for the qualitative determination of SARS-CoV-2 (Severe acute respiratory syndrome coronavirus 2) genomic RNA extracted from human respiratory (nasal wash/swab, nasopharyngeal wash/swab, oropharyngeal swab and bronchoalveolar lavage) specimen types. The assay simultaneously detects two target sequences inside the N gene while the multiplex PCR allows a streamlined workflow in one reaction and provides results in approximately two hours.
More details
Copyright © 2000-2021 TradeMed.com. All rights reserved. | Terms And Conditions